RE:RE:Takeover/Way UndervaluedThe $290M is the total debt of $3.4 billion that would be paid off multiplied by an 8.5% average interest rate = $290M. This would not have to be paid now. Originally I said that it would increase the EBITDA, but the EBITDA (which excludes interest on debt) of $520M would stay the same and the EBITDA minus interest would increase by $290M to $520M. This would give about a $520M yearly return or 12.4% ROI (return on investment) which is a great investment (along with an increased drug pipeline and 60 new drug launches in the next few years).